AUTHORS

Bruce Kamich
In addition to writing for theStreet.com Kamich has been teaching technical analysis at Baruch College for the past twenty years.
Kamich was one of the earliest Chartered Market Technicians or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works" and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (MTAEF.org).
Recent Articles By The Author
West Fraser Timber Has Lumbered Along but Is Starting to Look Promising
The stock of the diversified wood products company keeps seeing buying interest at a key level.
For 3M, It's a Tale of the Tape (and the Downward Sloping Charts)
With earnings set for Tuesday, let's see what the indicators say for this Dow name.
How to Play Qualcomm's Improved Technical Picture
Here's our latest strategy for the chipmaker.
At Least Investors Can Have Trust in the Media
The Communication Services Select Sector SPDR exchange-traded fund shows promise, according to the charts.
Trading Natural Gas Futures Can Feel Like a Real Circus ...
As we check the levels on gas futures for a possible bottom reversal, we find spinning tops and other odd formations that can guide investors.
With Spotify, It's Important to Pick the Right Spot to Buy
Pay attention to these price levels as the music and podcasting stock rises on layoff news.
Johnson & Johnson Might Need a Band-Aid Ahead of Earnings
A rally in the shares stalled around $180 in December and early January.
Boeing Has Been Rising but Its Ascent Has Stalled in Advance of Earnings
Traders and investors might be wise to display caution ahead of the aircraft giant reporting fourth-quarter results.
Salesforce Draws an Activist's Interest, So Should You Go Long?
Let's check the charts and indicators as Elliott Management takes a stake.
Incyte Gets a Quantitative Upgrade
We have two price target areas for this biopharmaceutical firm.
Oops!
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Please Join or Log In to Email Our Authors.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login